Tirzepatide Changes - We’re actively updating for compounded compliance changes
Date Published
- Twitter
- Facebook
- LinkedIn
- Instagram
- Copy Link
Today, March 19, 2025, is the deadline for 503B compounding pharmacies to stop making essential copies of tirzepatide. This means you should expect to see a lot of changes to the compounded tirzepatide options over the next few days.
We’re working hard to keep things updated but give us some grace to work with providers who are potentially changing their offerings around tirzepatide. We expect many to stop offering it, or only offer it in customized, less common, formulations.
What does this mean?
If the name brand medication and dosing would work for your treatment, you may not qualify for compounded tirzepatide. Patients need a medical justification and customized medication to qualify.
Is compounded tirzepatide going away?
It will not be as accessible as it has been and needs a medical justification. You will need to talk with your prescriber to see if you qualify to stay on compounded tirzepatide. It’s possible you have already been on a customized dose and no change is needed.
What will qualify someone for compounded tirzepatide?
They need a medical justification for why Mounjaro or Zepbound would not work for them.
Some examples might include:
- Allergies to something in Zepbound
- Standard dosing of 2.5, 5, 7.5, 10, 12, or 15mg will not work for you. You can not tolerate these doses.
- Have a medical justification for a different formulation that includes tirzepatide and other things.
We do not know if tirzepatide will stick around in these conditions. We expect Eli Lily to litigate those offering it. We do not know what the outcome of the litigation will be. We expect to see many providers stop offering tirzepatide to avoid litigation.
If you’re losing your compounded tizepatide access we will do our best to support you with other options including compounded semaglutide, and name brand medications.
We’re really flattered when Eli Lily thinks we’re a great resource and cites us in their cease and desist letters, but we want to mention that things are changing rapidly. We try to keep our information up to date but expect things to be less reliable while providers adjust or remove their tirzepatide offerings.
Keep Reading
Categories
Curated by
